Activation of the FGFR–STAT3 Pathway in Breast Cancer Cells Induces a Hyaluronan-Rich Microenvironment That Licenses Tumor Formation
Authors:
- Pavlina ChuntovaPCPavlina Chuntova
- Lindsey K. BadeLBLindsey K. Bade
- Thomas C. BeadnellTBThomas C. Beadnell
- Ronald P. LeonRLRonald P. Leon
- Nicholas J. BradyNBNicholas J. Brady
- Yungil RyuYRYungil Ryu
- Jodi E. GoldbergJGJodi E. Goldberg
- Stephen C. SchmechelSSStephen C. Schmechel
- Joseph S. KoopmeinersJKJoseph S. Koopmeiners
- James B. McCarthyJMJames B. McCarthy
- Kathryn L. SchwertfegerKSKathryn L. Schwertfeger
- 1 January 2014
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 74 (1) , 374-386
Abstract
Aberrant activation of fibroblast growth factor receptors (FGFR) contributes to breast cancer growth, progression, and therapeutic resistance. Because of the complex nature of the FGF/FGFR axis, and the numerous effects of FGFR activation on tumor cells and the surrounding microenvironment, the specific mechanisms through which aberrant FGFR activity contributes to breast cancer are not completely understood. We show here that FGFR activation induces accumulation of hyaluronan within the extracellular matrix and that blocking hyaluronan synthesis decreases proliferation, migration, and therapeutic resistance. Furthermore, FGFR-mediated hyaluronan accumulation requires activation of the STAT3 pathway, which regulates expression of hyaluronan synthase 2 (HAS2) and subsequent hyaluronan synthesis. Using a novel in vivo model of FGFR-dependent tumor growth, we demonstrate that STAT3 inhibition decreases both FGFR-driven tumor growth and hyaluronan levels within the tumor. Finally, our results suggest that combinatorial therapies inhibiting both FGFR activity and hyaluronan synthesis is more effective than targeting either pathway alone and may be a relevant therapeutic approach for breast cancers associated with high levels of FGFR activity. In conclusion, these studies indicate a novel targetable mechanism through which FGFR activation in breast cancer cells induces a protumorigenic microenvironment. Cancer Res; 74(1); 374–86. ©2013 AACR.Keywords
All Related Versions
This publication has 57 references indexed in Scilit:
- Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast CancerClinical Cancer Research, 2013
- Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical PerspectivesCancer Discovery, 2013
- Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer modelsBreast Cancer Research, 2013
- A RHAMM Mimetic Peptide Blocks Hyaluronan Signaling and Reduces Inflammation and Fibrogenesis in Excisional Skin WoundsThe American Journal of Pathology, 2012
- Hyaluronan-CD44 Interactions in Cancer: Paradoxes and PossibilitiesClinical Cancer Research, 2009
- STATs in cancer inflammation and immunity: a leading role for STAT3Nature Reviews Cancer, 2009
- 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3Experimental Cell Research, 2009
- Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesisBreast Cancer Research, 2009
- Activation of Stat3 in Primary Tumors from High-Risk Breast Cancer Patients Is Associated with Elevated Levels of Activated Src and Survivin ExpressionClinical Cancer Research, 2006
- Hyaluronan: from extracellular glue to pericellular cueNature Reviews Cancer, 2004